Autoimmune Thrombocytopenia
8
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
IASO-782 in Autoimmune Hematological Diseases
Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus
Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia
The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.